Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer
Conditions: Early Breast Cancer Interventions: Drug: Dalpiciclib; Drug: Endocrine therapy Sponsors: The First Affiliated Hospital with Nanjing Medical University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | Endocrine Therapy | HER2 | Hospitals | Research